Ying‐Nai Wang

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0002-5275-6729

发表论文 109 篇 · 总被引 3714 次 · h-index 33

代表论文

• Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma (2024 · Nature Communications · 被引 24)
• TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma (2025 · Blood · 被引 9)
• RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer (2025 · Signal Transduction and Targeted Therapy · 被引 8)
• FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models (2025 · Journal of Clinical Investigation · 被引 6)
• All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer (2024 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 6)
• All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer (2026 · Nature Communications · 被引 2)